Int. J. Environ. Res. Public Health 2012, 9 904 Figure 3. Phylogenetic tree based on the partial nucleotide sequences of NSP2 gene (150 bp) of RVB strains. The strains of the present study are in bold face. Scale indicates genetic distance. M-656 RVB/Human-wt/IND/CAL-1/1998 M-679 M-633 RVB/Human-wt/BGD/Bang-373/2000 M-856 52 M-346 M-781 RVB/Human-wt/IND/IDH-084/ 2007 M-634 M-714 76 MM--638123 M-367 RVB/Human-wt/MMR/MMR-B1/2007 RVB/Human-wt/CHN/ADRV/1982 97 RVB/Human-wt/CHN/ WH-1/2002 RVX/Human-wt/CHN/J19/1997 G2 (Indian-Bangladeshi lineage) G2 (Chinese lineage)  3.4.3. NoV 0.05  All of the 16 [nine (March) and seven (October)] NoV strains sequenced for RdRp gene (126 bp) showed the presence of NoV GII and absence of NoV GI. Ten [62.5%, six (March) and four (October)] of the 16 strains were genotyped (Table 3). Phylogenetically, five (50%) strains clustered in Hunter sub-cluster of GII.4 indicating 98.0–98.5% nucleotide identities with the Hunter 248/04/AU (DQ078794) strain. Two (20%), one (10%) and one (10%) strains showed GII.2, GII.7 and GII.12 specificities and presented 97%, 95.8% and 94.6% nucleotide identities, respectively, with the reference strains Melksham/95/UK (X81879), Leeds/90/US (AJ277608) and Wortley/90/UK (AJ277618) (Figure 4). The remaining one (10%) strain, M844, showed the presence of recombination with GII.3 and GII.13 specificities of RdRP and capsid genes, respectively in contiguous sequence. This strain showed 86.9% and 97% nucleotide identity with the reference strains TV24/94/US (U02030, GII.3) and Fayetteville/98/US (AY113106, GII.13) in RdRP and capsid regions, respectively. 3.4.4. AdV Sequence analysis of hexon gene (300 bp) from 16 [nine (March) and seven (October)] AdV strains revealed clustering of 13 [81.2%, seven (March) and six (October)] with the AdV type 40, Dugan strain (M18288, UK), two (12.5%, all from March) with the AdV type 12 Huie strain (AB330093, Japan) and one (6.3% from October) with Austrian AdV type 31 strain (DQ149611) with 97.3–100% nucleotide identities (Figure 5, Table 3).